Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, ...
In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...
At Envision Summit 2026, the “Fast and Fundus” retina panel delivered rapid-fire case discussions grounded in practical ...
According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. Although rare, semaglutide initiation can lead to ...
Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...
Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.
Ophthalmology Times, hosted by Douglas D. Koch, MD, Professor and Allen, Mosbacher, and Law Chair in Ophthalmology at the ...
In this Q&A article with the Eye Care Network, Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses the role of low- and middle-income country (LMIC) data in informing US ophthalmology clinical trials, ...
More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...
Larissa Camejo, MD: I’m a glaucoma specialist and the owner of a solo private practice in Palm Beach Gardens, Florida. Our ...
As the use of glaucoma drainage implants (GDIs) continues to expand in clinical practice, surgeons are becoming more attuned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results